Development of pharmacological strategies for mitochondrial disorders

British Journal of Pharmacology

Volumn 171, Issue 8, 2014, Pages 1798-1817

  Kanabus, M ^a   Heales, S J ^a,b,c   Rahman, S ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

clinical trials for mitochondrial disorders; gene therapy for mitochondrial diseases; mitochondrial biogenesis; mitochondrial diseases; models for mitochondrial disorders; nutritional and cofactor support in mitochondrial disorders; treatments for mitochondrial disorders

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ANTIOXIDANT; ARGININE; BEZAFIBRATE; CITRULLINE; CREATINE; CYSTEINE; DICHLOROACETIC ACID; DIMETHYLGLYCINE; MITOCHONDRIAL DNA; NUCLEASE; PLACEBO; REACTIVE OXYGEN METABOLITE; RESVERATROL; TAURINE; THIOCTIC ACID; UBIDECARENONE; VATIQUINONE;

CELL MEMBRANE FLUIDITY; CELL TRANSFER; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CLINICAL TRIAL (TOPIC); COMPLEX I DEFICIENCY; CYTOCHROME C OXIDASE DEFICIENCY; DIET THERAPY; DISEASE COURSE; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG TARGETING; ENZYME REPLACEMENT; FOLIC ACID DEFICIENCY; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; KETOGENIC DIET; KINESIOTHERAPY; LACTIC ACIDOSIS; LEIGH DISEASE; MELAS SYNDROME; MERRF SYNDROME; MITOCHONDRIAL DNA DEPLETION SYNDROME; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL GENETICS; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MITOPHAGY; MOUSE MODEL; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; OXIDATIVE PHOSPHORYLATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY CHAIN; REVIEW; SAGUENAY LAC SAINT JEAN CYTOCHROME C OXIDASE DEFICIENCY; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; MITOCHONDRIAL DISEASES; MITOCHONDRIAL DYNAMICS; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GENETIC THERAPY; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MITOCHONDRIAL TURNOVER; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; OXIDATIVE PHOSPHORYLATION;

EID: 84897461671     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12456     Document Type: Review

References (201)

1. Adhihetty PJ, Taivassalo T, Haller RG, Walkinshaw DR, Hood DA, (2007). The effect of training on the expression of mitochondrial biogenesis- and apoptosis-related proteins in skeletal muscle of patients with mtDNA defects. Am J Physiol Endocrinol Metab 293: E672-E680.
2. Agostino A, Invernizzi F, Tiveron C, Fagiolari G, Prelle A, Lamantea E, et al. (2003). Constitutive knockout of Surf1 is associated with high embryonic lethality, mitochondrial disease and cytochrome c oxidase deficiency in mice. Hum Mol Genet 12: 399-413.
3. Ahola-Erkkila S, Carroll CJ, Peltola-Mjosund K, Tulkki V, Mattila I, Seppanen-Laakso T, et al. (2010). Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet 19: 1974-1984.
4. Akman HO, Dorado B, Lopez LC, Garcia-Cazorla A, Vila MR, Tanabe LM, et al. (2008). Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. Hum Mol Genet 17: 2433-2440.
5. Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, et al. (2000). OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 26: 211-215.
6. Alfadhel M, Almuntashri M, Jadah RH, Bashiri FA, Al Rifai MT, Al Shalaan H, et al. (2013). Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet J Rare Dis 8: 83.
7. Allen RJ, DiMauro S, Coulter DL, Papadimitriou A, Rothenberg SP, (1983). Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann Neurol 13: 679-682.
8. Andreux PA, Houtkooper RH, Auwerx J, (2013). Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov 12: 465-483.
9. Bacman SR, Williams SL, Pinto M, Peralta S, Moraes CT, (2013). Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat Med 19: 1111-1113.
10. Bastin J, Lopes-Costa A, Djouadi F, (2011). Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts. Hum Mol Genet 20: 2048-2057.
11. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, et al. (2009). Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74: 619-624.
12. Bonnefont JP, Bastin J, Laforet P, Aubey F, Mogenet A, Romano S, et al. (2010). Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 88: 101-108.
13. Bough KJ, Wetherington J, Hassel B, Pare JF, Gawryluk JW, Greene JG, et al. (2006). Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 60: 223-235.
14. Bratic A, Larsson NG, (2013). The role of mitochondria in aging. J Clin Invest 123: 951-957.
15. Bredenoord AL, Braude P, (2010). Ethics of mitochondrial gene replacement: from bench to bedside. BMJ 341: c6021.
16. Bugiani M, Lamantea E, Invernizzi F, Moroni I, Bizzi A, Zeviani M, et al. (2006). Effects of riboflavin in children with complex II deficiency. Brain Dev 28: 576-581.
17. Bulst S, Abicht A, Holinski-Feder E, Muller-Ziermann S, Koehler U, Thirion C, et al. (2009). In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromes. Hum Mol Genet 18: 1590-1599.
18. Bulst S, Holinski-Feder E, Payne B, Abicht A, Krause S, Lochmuller H, et al. (2012). In vitro supplementation with deoxynucleoside monophosphates rescues mitochondrial DNA depletion. Mol Genet Metab 107: 95-103.
19. Byrd DJ, Krohn HP, Winkler L, Steinborn C, Hadam M, Brodehl J, et al. (1989). Neonatal pyruvate dehydrogenase deficiency with lipoate responsive lactic acidaemia and hyperammonaemia. Eur J Pediatr 148: 543-547.
20. Calvo S, Jain M, Xie X, Sheth SA, Chang B, Goldberger OA, et al. (2006). Systematic identification of human mitochondrial disease genes through integrative genomics. Nat Genet 38: 576-582.
21. Camara Y, Gonzalez-Vioque E, Scarpelli M, Torres-Torronteras J, Marti R, (2013). Feeding the deoxyribonucleoside salvage pathway to rescue mitochondrial DNA. Drug Discov Today 18: 950-957.
22. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. (2009). AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 1056-1060.
23. Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, et al. (2008). Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell 14: 193-204.
24. Cherry AB, Gagne KE, McLoughlin EM, Baccei A, Gorman B, Hartung O, et al. (2013). Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells 31: 1287-1297.
25. Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, et al. (2013). Barth syndrome. Orphanet J Rare Dis 8: 23.
26. Comte C, Tonin Y, Heckel-Mager AM, Boucheham A, Smirnov A, Aure K, et al. (2013). Mitochondrial targeting of recombinant RNAs modulates the level of a heteroplasmic mutation in human mitochondrial DNA associated with Kearns Sayre syndrome. Nucleic Acids Res 41: 418-433.
27. van de Corput MP, van den Ouweland JM, Dirks RW, Hart LM, Bruining GJ, Maassen JA, et al. (1997). Detection of mitochondrial DNA deletions in human skin fibroblasts of patients with Pearson's syndrome by two-color fluorescence in situ hybridization. J Histochem Cytochem 45: 55-61.
28. Coskun P, Wyrembak J, Schriner SE, Chen HW, Marciniack C, Laferla F, et al. (2012). A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta 1820: 553-564.
29. Craven L, Tuppen HA, Greggains GD, Harbottle SJ, Murphy JL, Cree LM, et al. (2010). Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature 465: 82-85.
30. Csiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, et al. (2009). Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 297: H13-H20.
31. Dassa EP, Dufour E, Gonçalves S, Paupe V, Hakkaart GA, Jacobs HT, et al. (2009). Expression of the alternative oxidase complements cytochrome c oxidase deficiency in human cells. EMBO Mol Med 1: 30-36.
32. De Stefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL, (1995). Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 45: 1193-1198.
33. De Vocht C, Ranquin A, Van GJ, Vanhaecke T, Rogiers V, Van GP, et al. (2010). Polymeric nanoreactors for enzyme replacement therapy of MNGIE. J Control Release 148: e19-e20.
34. Debattisti V, Scorrano L, (2013). D. melanogaster, mitochondria and neurodegeneration: small model organism, big discoveries. Mol Cell Neurosci 55: 77-86.
35. Delatycki MB, (2012). An open label clinical pilot study of resveratrol as treatment for friedreich ataxia. NCT01339884. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01339884?term=NCT01339884&rank=1 (accessed 20 August 2013).
36. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, et al. (2000). Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 26: 207-210.
37. Desnick RJ, Schuchman EH, (2012). Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet 13: 307-335.
38. Di Meo I, Auricchio A, Lamperti C, Burlina A, Viscomi C, Zeviani M, (2012). Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. EMBO Mol Med 4: 1008-1014.
39. Diaz F, Thomas CK, Garcia S, Hernandez D, Moraes CT, (2005). Mice lacking COX10 in skeletal muscle recapitulate the phenotype of progressive mitochondrial myopathies associated with cytochrome c oxidase deficiency. Hum Mol Genet 14: 2737-2748.
40. DiMauro S, (1999). Mitochondrial encephalomyopathies: back to Mendelian genetics. Ann Neurol 45: 693-694.
41. DiMauro S, (2013). Mitochondrial encephalomyopathies-fifty years on: the Robert Wartenberg Lecture. Neurology 81: 281-291.
42. DiMauro S, Mancuso M, (2007). Mitochondrial diseases: therapeutic approaches. Biosci Rep 27: 125-137.
43. Dominy JE, Puigserver P, (2013). Mitochondrial biogenesis through activation of nuclear signaling proteins. Cold Spring Harb Perspect Biol 5: 1-16.
44. Duncan AJ, Bitner-Glindzicz M, Meunier B, Costello H, Hargreaves IP, Lopez LC, et al. (2009). A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet 84: 558-566.
45. Duncan GE, Perkins LA, Theriaque DW, Neiberger RE, Stacpoole PW, (2004). Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism. J Clin Endocrinol Metab 89: 1733-1738.
46. El-Hattab AW, Hsu JW, Emrick LT, Wong LJ, Craigen WJ, Jahoor F, et al. (2012). Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. Mol Genet Metab 105: 607-614.
47. El-Khoury R, Dufour E, Rak M, Ramanantsoa N, Grandchamp N, Csaba Z, et al. (2013). Alternative oxidase expression in the mouse enables bypassing cytochrolme c oxidase blockade and limits mitochondrial ROS overproduction. PLoS Genet 9: e1003182.
48. Ellouze S, Augustin S, Bouaita A, Bonnet C, Simonutti M, Forster V, et al. (2008). Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet 83: 373-387.
49. Enns GM, Kinsman SL, Perlman SL, Spicer KM, Abdenur JE, Cohen BH, et al. (2012). Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 105: 91-102.
50. Fassone E, Wedatilake Y, DeVile C, Chong WK, Carr LJ, Rahman S, (2013). Treatable Leigh-like encephalopathy presenting in adolescence. BMJ Case Rep (in press). doi. 10.1136/bcr-2013-200838.
51. Fernandez-Ayala DJ, Chen S, Kemppainen E, O'Dell KM, Jacobs HT, (2010). Gene expression in a Drosophila model of mitochondrial disease. PLoS ONE 5: e8549.
52. Ferreira LF, Campbell KS, Reid MB, (2011). N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions. Int J Sport Nutr Exerc Metab 21: 146-154.
53. Foley AR, Menezes MP, Pandraud A, Gonzalez MA, Al-Odaib A, Abrams AJ, et al. (2013). Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain (in press).
54. Garcia-Corzo L, Luna-Sanchez M, Doerrier C, Garcia JA, Guaras A, Acin-Perez R, et al. (2013). Dysfunctional Coq9 protein causes predominant encephalomyopathy associated with CoQ deficiency. Hum Mol Genet 22: 1233-1248.
55. Gerards M, van den Bosch BJ, Danhauser K, Serre V, van Weeghel M, Wanders RJ, et al. (2011). Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene. Brain 134: 210-219.
56. Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA, (2010). A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 42: 739-748.
57. Golubitzky A, Dan P, Weissman S, Link G, Wikstrom JD, Saada A, (2011). Screening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound. PLoS ONE 6: e26883.
58. Grad LI, Lemire BD, (2006). Riboflavin enhances the assembly of mitochondrial cytochrome c oxidase in C. elegans NADH-ubiquinone oxidoreductase mutants. Biochim Biophys Acta 1757: 115-122.
59. Graham BH, Waymire KG, Cottrell B, Trounce IA, Macgregor GR, Wallace DC, (1997). A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 16: 226-234.
60. Haller RG, (2009). Exercise training and deconditions: implications for therapy in mitochondrial myopathy. NCT00457314. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00457314?term=NCT00457314&rank=1 (accessed 20 August 2013).
61. Halter J, Schupbach WM, Casali C, Elhasid R, Fay K, Hammans S, et al. (2011). Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant 46: 330-337.
62. Hance N, Ekstrand MI, Trifunovic A, (2005). Mitochondrial DNA polymerase gamma is essential for mammalian embryogenesis. Hum Mol Genet 14: 1775-1783.
63. Hardie DG, (2007). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785.
64. Hargreaves IP, Sheena Y, Land JM, Heales SJ, (2005). Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment. J Inherit Metab Dis 28: 81-88.
65. Hargreaves IP, Duncan AJ, Wu L, Agrawal A, Land JM, Heales SJ, (2007). Inhibition of mitochondrial complex IV leads to secondary loss complex II-III activity: implications for the pathogenesis and treatment of mitochondrial encephalomyopathies. Mitochondrion 7: 284-287.
66. Hayashi M, Imanaka-Yoshida K, Yoshida T, Wood M, Fearns C, Tatake RJ, et al. (2006). A crucial role of mitochondrial Hsp40 in preventing dilated cardiomyopathy. Nat Med 12: 128-132.
67. Heales SJ, Bolanos JP, Land JM, Clark JB, (1994). Trolox protects mitochondrial complex IV from nitric oxide-mediated damage in astrocytes. Brain Res 668: 243-245.
68. Heales SJ, Bolanos JP, Brand MP, Clark JB, Land JM, (1996). Mitochondrial damage: an important feature in a number of inborn errors of metabolism? J Inherit Metab Dis 19: 140-142.
69. Heller A, Brockhoff G, Goepferich A, (2012). Targeting drugs to mitochondria. Eur J Pharm Biopharm 82: 1-18.
70. House of Commons Hansard Debates 25 June 2013 (2013). Mitochondrial disease. UK Parliment 565 c60WH. Available at: http://www.publications. parliament.uk/pa/cm201314/cmhansrd/cm130625/halltext/130625h0002. htm#13062568000002 (accessed 20 August 2013).
71. Hyland K, Shoffner J, Heales SJ, (2010). Cerebral folate deficiency. J Inherit Metab Dis 33: 563-570.
72. Inoue K, Nakada K, Ogura A, Isobe K, Goto Y, Nonaka I, et al. (2000). Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. Nat Genet 26: 176-181.
73. Jacobson J, Duchen MR, Hothersall J, Clark JB, Heales SJ, (2005). Induction of mitochondrial oxidative stress in astrocytes by nitric oxide precedes disruption of energy metabolism. J Neurochem 95: 388-395.
74. Jager S, Handschin CS, Pierre J, Spiegelman BM, (2007). AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 104: 12017-12022.
75. Jarrett SG, Milder JB, Liang LP, Patel M, (2008). The ketogenic diet increases mitochondrial glutathione levels. J Neurochem 106: 1044-1051.
76. Kang HC, Lee YM, Kim HD, Lee JS, Slama A, (2007). Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 48: 82-88.
77. Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, et al. (2006). Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 66: 324-330.
78. Ke BX, Pepe S, Grubb DR, Komen JC, Laskowski A, Rodda FA, et al. (2012). Tissue-specific splicing of an Ndufs6 gene-trap insertion generates a mitochondrial complex I deficiency-specific cardiomyopathy. Proc Natl Acad Sci U S A 109: 6165-6170.
79. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, et al. (2001). Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 276: 4588-4596. J Biol Chem 282: 14708-14718.
80. Kerr DS, (2013). Review of clinical trials for mitochondrial disorders: 1997-2012. Neurother 10: 307-319.
81. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H, (2003). Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 34: 440-445.
82. King MP, Attardi G, (1989). Human cells lacking mtDNA: repopulation with exogenous rhorhomitochondria by complementation. Science 246: 500-503.
83. Klein M, (2012). A phase 2B randomized, placebo controlled, double blind clinical trial of EPI-743 in children with leigh syndrome. NCT01721733. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01721733?term= NCT01721733&rank=1 (accessed 20 August 2013).
84. Klopstock T, Querner V, Schmidt F, Gekeler F, Walter M, Hartard M, et al. (2000). A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 55: 1748-1751.
85. Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, et al. (2011). A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 134: 2677-2686.
86. Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Tanabe Y, et al. (2005). L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 64: 710-712.
87. Koga Y, Akita Y, Junko N, Yatsuga S, Povalko N, Fukiyama R, et al. (2006). Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology 66: 1766-1769.
88. Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T, (2010). MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann N Y Acad Sci 1201: 104-110.
89. Kornblum C, Schroder R, Muller K, Vorgerd M, Eggers J, Bogdanow M, et al. (2005). Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. Eur J Neurol 12: 300-309.
90. Krishnan S, Zhou X, Paredes JA, Kuiper RV, Curbo S, Karlsson A, (2013). Transgene expression of Drosophila melanogaster nucleoside kinase reverses mitochondrial thymidine kinase 2 deficiency. J Biol Chem 288: 5072-5079.
91. Kruse SE, Watt WC, Marcinek DJ, Kapur RP, Schenkman KA, Palmiter RD, (2008). Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy. Cell Metab 7: 312-320.
92. Lam BL, Feuer WJ, Abukhalil F, Porciatti V, Hauswirth WW, Guy J, (2010). Leber hereditary optic neuropathy gene therapy clinical trial recruitment: year 1. Arch Ophthalmol 128: 1129-1135.
93. Lamari F, Mochel F, Sedel F, Saudubray JM, (2013). Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases. J Inherit Metab Dis 36: 411-425.
94. Larsson NG, Wang J, Wilhelmsson H, Oldfors A, Rustin P, Lewandoski M, et al. (1998). Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet 18: 231-236.
95. Laugel V, This-Bernd V, Cormier-Daire V, Speeg-Schatz C, de Saint-Martin A, Fischbach M, (2007). Early-onset ophthalmoplegia in Leigh-like syndrome due to NDUFV1 mutations. Pediatr Neurol 36: 54-57.
96. Leveen P, Kotarsky H, Morgelin M, Karikoski R, Elmer E, Fellman V, (2011). The GRACILE mutation introduced into Bcs1l causes postnatal complex III deficiency: a viable mouse model for mitochondrial hepatopathy. Hepatology 53: 437-447.
97. Levene M, Coleman DG, Kilpatrick HC, Fairbanks LD, Gangadharan B, Gasson C, et al. (2013). Preclinical toxicity evaluation of erythrocyte-encapsulated thymidine phosphorylase in BALB/c mice and beagle dogs: an enzyme-replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy. Toxicol Sci 131: 311-324.
98. Libri V, Brown AP, Gambarota G, Haddad J, Shields GS, Dawes H, et al. (2012). A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS ONE 7: e51395.
99. Liet JM, Pelletier V, Robinson BH, Laryea MD, Wendel U, Morneau S, et al. (2003). The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. J Pediatr 142: 62-66.
100. Lin CS, Sharpley MS, Fan W, Waymire KG, Sadun AA, Carelli V, et al. (2012). Mouse mtDNA mutant model of Leber hereditary optic neuropathy. Proc Natl Acad Sci U S A 109: 20065-20070.
101. Lyon MF, Hulse EV, (1971). An inherited kidney disease of mice resembling human nephronophthisis. J Med Genet 8: 41-48.
102. Lyrawati D, Trounson A, Cram D, (2011). Expression of GFP in the mitochondrial compartment using DQAsome-mediated delivery of an artificial mini-mitochondrial genome. Pharm Res 28: 2848-2862.
103. Mahata B, Mukherjee S, Mishra S, Bandyopadhyay A, Adhya S, (2006). Functional delivery of a cytosolic tRNA into mutant mitochondria of human cells. Science 314: 471-474.
104. Malojcic B, Brinar V, Poser C, Djakovic V, (2004). An adult case of Leigh disease. Clin Neurol Neurosurg 106: 237-240.
105. Mancuso M, Orsucci D, Logerfo A, Rocchi A, Petrozzi L, Nesti C, et al. (2010). Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol 257: 774-781.
106. Mancuso M, Orsucci D, Angelini C, Bertini E, Carelli V, Comi GP, et al. (2013). Phenotypic heterogeneity of the 8344A>G mtDNA 'MERRF' mutation. Neurology 80: 2049-2054.
107. Manfredi G, Fu J, Ojaimi J, Sadlock JE, Kwong JQ, Guy J, et al. (2002). Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat Genet 30: 394-399.
108. Marella M, Seo BB, Thomas BB, Matsuno-Yagi A, Yagi T, (2010). Successful amelioration of mitochondrial optic neuropathy using the yeast NDI1 gene in a rat animal model. PLoS ONE 5: e11472.
109. Mari M, Morales A, Colell A, Garcia-Ruiz C, Fernandez-Checa JC, (2009). Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 11: 2685-2700.
110. Martinelli D, Catteruccia M, Piemonte F, Pastore A, Tozzi G, et al. (2012). EPI-743 reverses the progression of the pediatric mitochondrial disease-genetically defined Leigh Syndrome. Mol Genet Metab 107: 383-388.
111. Mayr JA, Zimmermann FA, Fauth C, Bergheim C, Meierhofer D, Radmayr D, et al. (2011). Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. Am J Hum Genet 89: 792-797.
112. Mayr JA, Haack TB, Graf E, Zimmermann FA, Wieland T, Haberberger B, et al. (2012). Lack of the mitochondrial protein acylglycerol kinase causes Sengers syndrome. Am J Hum Genet 90: 314-320.
113. Michot C, Hubert L, Romero NB, Gouda A, Mamoune A, Mathew S, et al. (2012). Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia. J Inherit Metab Dis 35: 1119-1128.
114. Mitsuhashi S, Ohkuma A, Talim B, Karahashi M, Koumura T, Aoyama C, et al. (2011). A congenital muscular dystrophy with mitochondrial structural abnormalities caused by defective de novo phosphatidylcholine biosynthesis. Am J Hum Genet 88: 845-851.
115. Monteiro JP, Oliveira PJ, Jurado AS, (2013). Mitochondrial membrane lipid remodeling in pathophysiology: a new target for diet and therapeutic interventions. Prog Lipid Res 52: 513-528.
116. Montini G, Malaventura C, Salviati L, (2008). Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med 358: 2849-2850.
117. Moran NF, Bain MD, Muqit MM, Bax BE, (2008). Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE. Neurology 71: 686-688.
118. Munnich A, Rustin P, Rotig A, Chretien D, Bonnefont JP, Nuttin C, et al. (1992). Clinical aspects of mitochondrial disorders. J Inherit Metab Dis 15: 448-455.
119. Murphy JL, Blakely EL, Schaefer AM, He L, Wyrick P, Haller RG, et al. (2008). Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 131: 2832-2840.
120. Naini A, Kaufmann P, Shanske S, Engelstad K, De Vivo DC, Schon EA, (2005). Hypocitrullinemia in patients with MELAS: an insight into the 'MELAS paradox'. J Neurol Sci 229-230: 187-193.
121. Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, et al. (2013). The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation-implications for diagnosis and management. J Neurol Neurosurg Psychiatry 84: 936-938.
122. Nuffield Council on Bioethics UK (2012). Novel techniques for the prevention of mitochondrial DNA disorders: an ethical review. Available at: http://www.nuffieldbioethics.org/sites/default/files/Novel-techniques-for-the- prevention-of-mitochondrial-DNA-disorders-compressed.pdf (accessed 20 August 2013).
123. Nunnari J, Suomalainen A, (2012). Mitochondria: in sickness and in health. Cell 148: 1145-1159.
124. Ogle RF, Christodoulou J, Fagan E, Blok RB, Kirby DM, Seller KL, et al. (1997). Mitochondrial myopathy with tRNA(Leu(UUR)) mutation and complex I deficiency responsive to riboflavin. J Pediatr 130: 138-145.
125. Oguro H, Iijima K, Takahashi K, Nagai A, Bokura H, Yamaguchi S, et al. (2004). Successful treatment with succinate in a patient with MELAS. Intern Med 43: 427-431.
126. Oppenheim ML, Hargreaves IP, Pope S, Land JM, Heales SJ, (2009). Mitochondrial cytochrome c release: a factor to consider in mitochondrial disease? J Inherit Metab Dis 32: 269-273.
127. Orrenius S, Zhivotovsky B, (2005). Cardiolipin oxidation sets cytochrome c free. Nat Chem Biol 1: 188-189.
128. Patti ME, Corvera S, (2010). The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 31: 364-395.
129. Petrosillo G, Moro N, Ruggiero FM, Paradies G, (2009). Melatonin inhibits cardiolipin peroxidation in mitochondria and prevents the mitochondrial permeability transition and cytochrome c release. Free Radic Biol Med 47: 969-974.
130. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF, (2012). Treatment for mitochondrial disorders. Cochrane Database Syst Rev (4): CD004426.
131. Phoenix C, Schaefer AM, Elson JL, Morava E, Bugiani M, Uziel G, et al. (2006). A scale to monitor progression and treatment of mitochondrial disease in children. Neuromuscul Disord 16: 814-820.
132. Pineda M, Ormazabal A, Lopez-Gallardo E, Nascimento A, Solano A, Herrero MD, et al. (2006). Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion. Ann Neurol 59: 394-398.
133. Piruat JI, Pintado CO, Ortega-Saenz P, Roche M, Lopez-Barneo J, (2004). The mitochondrial SDHD gene is required for early embryogenesis, and its partial deficiency results in persistent carotid body glomus cell activation with full responsiveness to hypoxia. Mol Cell Biol 24: 10933-10940.
134. Pitts-Tucker T, (2012). UK fertilisation authority launches consultation on mitochondrial replacement techniques. BMJ 345: e6259.
135. Pope S, Land JM, Heales SJ, (2008). Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target? Biochim Biophys Acta 1777: 794-799.
136. Prescribing and Primary Care Services, Health and Social Care Information Centre (2012). Prescriptions dispensed in the community: England 2002-12. Available at: https://catalogue.ic.nhs.uk/publications/prescribing/primary/pres- disp-com-eng-2002-12/pres-disp-com-eng-2002-12-rep.pdf (accessed 20 August 2013).
137. Qi X, Qvit N, Su YC, Mochly-Rosen D, (2013). A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci 126: 789-802.
138. Rahman S, (2012). Mitochondrial disease and epilepsy. Dev Med Child Neurol 54: 397-406.
139. Rahman S, (2013). Gastrointestinal and hepatic manifestations of mitochondrial disorders. J Inherit Metab Dis 36: 659-673.
140. Rahman S, Hanna MG, (2009). Diagnosis and therapy in neuromuscular disorders: diagnosis and new treatments in mitochondrial diseases. J Neurol Neurosurg Psychiatry 80: 943-953.
141. Rahman S, Thorburn DR, (2013). 189th ENMC international workshop complex I deficiency: diagnosis and treatment 20-22 April 2012, Naarden, The Netherlands. Neuromuscul Disord 23: 506-515.
142. Rahman S, Hargreaves I, Clayton P, Heales S, (2001). Neonatal presentation of coenzyme Q10 deficiency. J Pediatr 139: 456-458.
143. Rahman S, Clarke CF, Hirano M, (2012). 176th ENMC International Workshop: diagnosis and treatment of coenzyme Q(1)(0) deficiency. Neuromuscul Disord 22: 76-86.
144. Rikimaru M, Ohsawa Y, Wolf AM, Nishimaki K, Ichimiya H, Kamimura N, et al. (2012). Taurine ameliorates impaired the mitochondrial function and prevents stroke-like episodes in patients with MELAS. Intern Med 51: 3351-3357.
145. Robinson BH, (1996). Use of fibroblast and lymphoblast cultures for detection of respiratory chain defects. Methods Enzymol 264: 454-464.
146. Robinson BH, Glerum DM, Chow W, Petrova-Benedict R, Lightowlers R, Capaldi R, (1990). The use of skin fibroblast cultures in the detection of respiratory chain defects in patients with lacticacidemia. Pediatr Res 28: 549-555.
147. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA, (2007). Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 35: 235-242.
148. Roef MJ, de Meer K, Reijngoud DJ, Straver HW, de Barse M, et al. (2002a). Triacylglycerol infusion does not improve hyperlactemia in resting patients with mitochondrial myopathy due to complex I deficiency. Am J Clin Nutr 75: 228-236.
149. Roef MJ, de Meer K, Reijngoud DJ, Straver HW, de Barse M, Kalhan SC, et al. (2002b). Triacylglycerol infusion improves exercise endurance in patients with mitochondrial myopathy due to complex I deficiency. Am J Clin Nutr 75: 237-244.
150. Rötig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, et al. (1997). Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17: 215-217.
151. Salmi H, Leonard JV, Rahman S, Lapatto R, (2012). Plasma thiol status is altered in children with mitochondrial diseases. Scand J Clin Lab Invest 72: 152-157.
152. Santra S, Gilkerson RW, Davidson M, Schon EA, (2004). Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol 56: 662-669.
153. Schagger H, Pfeiffer K, (2000). Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. EMBO J 19: 1777-1783.
154. Schlame M, Ren M, (2006). Barth syndrome, a human disorder of cardiolipin metabolism. FEBS Lett 580: 5450-5455.
155. Scholte HR, Busch HF, Bakker HD, Bogaard JM, Luyt-Houwen IE, Kuyt LP, (1995). Riboflavin-responsive complex I deficiency. Biochim Biophys Acta 1271: 75-83.
156. Schwimmer C, Rak M, Lefebvre-Legendre L, Duvezin-Caubet S, Plane G, di Rago JP, (2006). Yeast models of human mitochondrial diseases: from molecular mechanisms to drug screening. Biotechnol J 1: 270-281.
157. Serrano M, Perez-Duenas B, Montoya J, Ormazabal A, Artuch R, (2012). Genetic causes of cerebral folate deficiency: clinical, biochemical and therapeutic aspects. Drug Discov Today 17: 1299-1306.
158. Shamseldin HE, Alshammari M, Al-Sheddi T, Salih MA, Alkhalidi H, Kentab A, et al. (2012). Genomic analysis of mitochondrial diseases in a consanguineous population reveals novel candidate disease genes. J Med Genet 49: 234-241.
159. Spector R, Johanson CE, (2010). Choroid plexus failure in the Kearns-Sayre syndrome. Cerebrospinal Fluid Res 7: 14.
160. Stacpoole PW, Barnes CL, Hurbanis MD, Cannon SL, Kerr DS, (1997). Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child 77: 535-541.
161. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, et al. (2006). Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 117: 1519-1531.
162. Stacpoole PW, deGrauw TJ, Feigenbaum AS, Hoppel C, Kerr DS, McCandless SE, et al. (2012). Design and implementation of the first randomized controlled trial of coenzyme CoQ(1)(0) in children with primary mitochondrial diseases. Mitochondrion 12: 623-629.
163. Stetler AR, Leak RK, Chen J, (2013). The dynamics of the mitochondrial organelle as a potential therapeutic target. J Cereb Blood Flow Metab 33: 22-32.
164. Sullivan PG, Rippy NA, Dorenbos K, Concepcion RC, Agarwal AK, Rho JM, (2004). The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann Neurol 55: 576-580.
165. Suomalainen A, (2011). Therapy for mitochondrial disorders: little proof, high research activity, some promise. Semin Fetal Neonatal Med 16: 236-240.
166. Suomalainen A, Elo JM, Pietilainen KH, Hakonen AH, Sevastianova K, Korpela M, et al. (2011). FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 10: 806-818.
167. Taanman JW, Muddle JR, Muntau AC, (2003). Mitochondrial DNA depletion can be prevented by dGMP and dAMP supplementation in a resting culture of deoxyguanosine kinase-deficient fibroblasts. Hum Mol Genet 12: 1839-1845.
168. Tachibana M, Sparman M, Sritanaudomchai H, Ma H, Clepper L, Woodward J, et al. (2009). Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 461: 367-372.
169. Tachibana M, Amato P, Sparman M, Woodward J, Sanchis DM, Ma H, et al. (2013). Towards germline gene therapy of inherited mitochondrial diseases. Nature 493: 627-631.
170. Taivassalo T, Fu K, Johns T, Arnold D, Karpati G, Shoubridge EA, (1999). Gene shifting: a novel therapy for mitochondrial myopathy. Hum Mol Genet 8: 1047-1052.
171. Taivassalo T, Shoubridge EA, Chen J, Kennaway NG, DiMauro S, Arnold DL, et al. (2001). Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann Neurol 50: 133-141.
172. Taivassalo T, Gardner JL, Taylor RW, Schaefer AM, Newman J, Barron MJ, et al. (2006). Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain 129: 3391-3401.
173. Tanaka M, Borgeld HJ, Zhang J, Muramatsu S, Gong JS, Yoneda M, et al. (2002). Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J Biomed Sci 9: 534-541.
174. Tarnopolsky MA, Roy BD, MacDonald JR, (1997). A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 20: 1502-1509.
175. Taylor RW, Turnbull DM, (2005). Mitochondrial DNA mutations in human disease. Nat Rev Genet 6: 389-402.
176. Thorburn DR, (2004). Mitochondrial disorders: prevalence, myths and advances. J Inherit Metab Dis 27: 349-362.
177. Toivonen JM, O'Dell KM, Petit N, Irvine SC, Knight GK, Lehtonen M, et al. (2001). Technical knockout, a Drosophila model of mitochondrial deafness. Genetics 159: 241-254.
178. Torres-Torronteras J, Gomez A, Eixarch H, Palenzuela L, Pizzorno G, et al. (2011). Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE. Gene Ther 18: 795-806.
179. Tyynismaa H, Mjosund KP, Wanrooij S, Lappalainen I, Ylikallio E, Jalanko A, et al. (2005). Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. Proc Natl Acad Sci U S A 102: 17687-17692.
180. Tyynismaa H, Carroll CJ, Raimundo N, Ahola-Erkkila S, Wenz T, Ruhanen H, et al. (2010). Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet 19: 3948-3958.
181. Vafai SB, Mootha VK, (2012). Mitochondrial disorders as windows into an ancient organelle. Nature 491: 374-383.
182. Viscomi C, Burlina AB, Dweikat I, Savoiardo M, Lamperti C, Hildebrandt T, et al. (2010). Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med 16: 869-871.
183. Viscomi C, Bottani E, Civiletto G, Cerutti R, Moggio M, Fagiolari G, et al. (2011). In vivo correction of COX deficiency by activation of the AMPK/PGC-1alpha axis. Cell Metab 14: 80-90.
184. Vissing J, Gansted U, Quistorff B, (2001). Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis. Ann Neurol 49: 672-676.
185. Wallace DC, Fan W, Procaccio V, (2010). Mitochondrial energetics and therapeutics. Annu Rev Pathol 5: 297-348.
186. Wang D, Wang J, Bonamy GM, Meeusen S, Brusch RG, Turk C, et al. (2012). A small molecule promotes mitochondrial fusion in mammalian cells. Angew Chem Int Ed Engl 51: 9302-9305.
187. Waterham HR, Koster J, van Roermund CW, Mooyer PA, Wanders RJ, Leonard JV, (2007). A lethal defect of mitochondrial and peroxisomal fission. N Engl J Med 356: 1736-1741.
188. Wedatilake Y, Brown R, McFarland R, Yaplito-Lee J, Morris AA, Champion M, et al. (2013). SURF1 deficiency: a multi-centre natural history study. Orphanet J Rare Dis 8: 96.
189. Weiher H, Noda T, Gray DA, Sharpe AH, Jaenisch R, (1990). Transgenic mouse model of kidney disease: insertional inactivation of ubiquitously expressed gene leads to nephrotic syndrome. Cell 62: 425-434.
190. Wenz T, Diaz F, Spiegelman BM, Moraes CT, (2008). Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 8: 249-256.
191. Wiedemann N, Frazier AE, Pfanner N, (2004). The protein import machinery of mitochondria. J Biol Chem 279: 14473-14476.
192. Wortmann SB, Vaz FM, Gardeitchik T, Vissers LE, Renkema GH, Schuurs-Hoeijmakers JH, et al. (2012). Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness. Nat Genet 44: 797-802.
193. Yagi T, Seo BB, Nakamaru-Ogiso E, Marella M, Barber-Singh J, Yamashita T, et al. (2006). Possibility of transkingdom gene therapy for complex I diseases. Biochim Biophys Acta 1757: 708-714.
194. Yamada Y, Akita H, Kogure K, Kamiya H, Harashima H, (2007). Mitochondrial drug delivery and mitochondrial disease therapy-an approach to liposome-based delivery targeted to mitochondria. Mitochondrion 7: 63-71.
195. Yang H, Brosel S, Acin-Perez R, Slavkovich V, Nishino I, Khan R, et al. (2010). Analysis of mouse models of cytochrome c oxidase deficiency owing to mutations in Sco2. Hum Mol Genet 19: 170-180.
196. Yasuzaki Y, Yamada Y, Harashima H, (2010). Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes. Biochem Biophys Res Commun 397: 181-186.
197. Yatsuga S, Suomalainen A, (2012). Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet 21: 526-535.
198. Yatsuga S, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T, et al. (2012). MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 1820: 619-624.
199. Zeharia A, Shaag A, Houtkooper RH, Hindi T, de Lonlay P, Erez G, et al.(2008). Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet 83: 489-494.
200. Zhou X, Solaroli N, Bjerke M, Stewart JB, Rozell B, Johansson M, et al. (2008). Progressive loss of mitochondrial DNA in thymidine kinase 2-deficient mice. Hum Mol Genet 17: 2329-2335.
201. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. (2004). Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36: 449-451.